Gapping up
In reaction to strong earnings/guidance:
- CHEK +6.6%, BZUN +4.3%, DDS +1.6%, WMT +1.4%, RIG +1.3%
M&A news:
- WPZ +1% (to be acquired by Williams (WMB) in a $10.5 bln all stock transaction)
Other news:
- LOXO +14.7% (LOXO-292 Phase 1 clinical trial abstract selected for "Best of ASCO")
- IMMU +7.6% (reports 'positive' data for sacituzumab govitecan, its metastatic breast cancer drug)
- ESND +6.1% (confirms receipt of merger proposal from Staples and Genuine Parts Company )
- NERV +5.4% (announces publication of results demonstrating cognitive improvements in patients with schizophrenia treated with roluperidone in The Journal of Clinical Psychiatry)
- CURO +4.2% (prices 5 mln shares of common stock by selling shareholders at $23.00 per share)
- EXEL +2.6% (partner Ipsen (IPSEY) receives approval from the European Commission for CABOMETYX 20 mg, 40 mg and 60 mg for the first-line treatment of adults with intermediate- or poor-risk advanced renal cell carcinoma)
- XNET +1.5% (launched StellarCloud and ThunderChain Open Platform to build a blockchain ecosystem)
Analyst comments:
- NI +1.7% (upgraded to Overweight from Neutral at JP Morgan )
- MANT +1.6% (upgraded to Outperform from Market Perform at Wells Fargo)
- VLO +1.3% (upgraded to Overweight from Equal-Weight at Morgan Stanley)
- KO +1% (upgraded to Overweight from Equal Weight at Barclays)
- AIG +0.9% (upgraded to Buy from Neutral at UBS)
- CE +0.9% (upgraded to Buy from Neutral at UBS )
- NUE +0.5% (upgraded to Outperform from Neutral at Macquarie)
![]()